Study wrapper · #329
Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women.
Editor's note
This is a clinician-focused review of drug options for HSDD in premenopausal women, and it is usefully candid about bremelanotide's limits. The authors note that flibanserin and bremelanotide are the only FDA-approved agents for generalized acquired HSDD in this group (with bupropion and buspirone used off-label), but they explicitly caution about limited efficacy, potential adverse effects, and transparency issues in trial reporting. That balanced, even skeptical, framing aligns with the broader evidence: bremelanotide's benefit is real but modest and its endpoints have been questioned. The review contains no new data; it synthesizes 25 years of literature and product monographs to guide individualized care and calls for further research using more suitable clinical endpoints before wide adoption. Weight it as a measured, practice-oriented reminder that approval is not the same as strong efficacy, and that patient selection and honest expectation-setting matter as much as the choice of agent.
Plain-language abstract
This review summarizes medication options for hypoactive sexual desire disorder (HSDD) — ongoing low sexual desire causing distress — in premenopausal women. The authors searched medical databases from 1999 to 2024 and reviewed official product information, focusing on human studies. They explain that only two medications, flibanserin and bremelanotide, are approved by the U.S. FDA for this condition in premenopausal women, while others like bupropion and buspirone are sometimes used off-label. Care, they emphasize, works best as a combined approach that also includes counseling and lifestyle changes. Notably, the authors urge caution about the approved drugs, pointing to their limited effectiveness, possible side effects, and concerns about how openly the trial results were reported. They stress using validated assessment tools to tailor care to each person, weighing potential benefits against risks and side effects, and note relevance for transgender individuals as well. Their overall message is that these medications can play a role but should be used thoughtfully, and that more research with better outcome measures is needed before they are adopted widely. This is a summary of existing evidence, not a new trial.